These are the topics which the National Institute for Health and Clinical Excellence has been invited to appraise. For each proposed appraisal, the table gives the suggested remit, the dates of the consultation on that remit, an e-mail address to send any enquiries to regarding the proposed appraisal, and links to any documents being consulted on in addition to the suggested remit.
|
Topic
|
Lung cancer (non-small-cell, advanced, relapsed/refractory) - sorafenib [ID522]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of sorafenib within its licence indication for the third or fourth line treatment of advanced, non-squamous non-small cell lung cancer.
|
|
Consultation on suggested remit, draft scope and provisional matrix of
|
21 March 2012- 20 April 2012
|
|
Scoping workshop
|
The National Institute for Health and Clinical Excellence (NICE) has been invited to carry out an appraisal of sorafenib for the third or fourth line treatment of advanced, non-squamous non-small cell lung cancer. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal.
The manufacturer of sorafenib has advised us that the pivotal trial for sorafenib in the third or fourth line treatment of advanced, non-squamous non-small cell lung cancer failed to meet it's primary endpoint so they are not currently pursuing a licence in the UK for this product.
In light of this information the Institute will not be progressing with the scoping exercise. Consequently the scoping workshop arranged for Tuesday 22 May 2012 was cancelled. We apologise for any inconvenience this may cause.
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Lung cancer (non-small-cell, advanced, metastatic) - nab paclitaxel [ID553]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of nab-paclitaxel in combination with carboplatin within its licensed indication for the first-line treatment of non-small cell lung cancer.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
21 March 2012- 20 April 2012
|
|
Scoping workshop
|
22 May 2012 (afternoon meeting) in London
The National Institute for Health and Clinical Excellence (NICE) has been invited to carry out an appraisal of nab-paclitaxel in combination with carboplatin for the first-line treatment of non-small cell lung cancer. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal.
Following information received from the manufacturer of nab-paclitaxel the scoping workshop arranged for Tuesday 22 May has been cancelled. We apologise for any inconvenience this may cause.
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Vitreomacular adhesion (symptomatic) - ocriplasmin (1st line) [ID544]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of ocriplasmin within its licensed indication for the first-line treatment of symptomatic vitreomacular adhesion.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
16 March 2012 - 17 April 2012
|
|
Scoping workshop
|
11 May 2012 (morning meeting) in Manchester (please note this workshop was previously arranged for the 15 May 2012)
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Multiple sclerosis (relapsing) - teriflunomide (1st line)[ID548]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of teriflunomide, within its licensed indication, for the treatment of relapsing forms of multiple sclerosis.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
19 March 2012 - 18 April 2012
|
|
Scoping workshop
|
21 May 2012 (morning meeting) in London
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Obesity - phentermine (with topiramate) [ID543]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of phentermine with topiramate within its licensed indication for the treatment of adults who are obese or who are overweight and have weight-related co-morbidities.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
05 January 2012 - 02 February 2012
|
|
Scoping workshop
|
19 March 2012 (morning meeting) in London
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Breast cancer (HER2 positive, metastatic) - pertuzumab [ID523]
|
|
Suggested remit
|
To appraise the clinical and cost-effectiveness of pertuzumab in combination with trastuzumab and a taxane within its licensed indication for the treatment of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
06 January 2012 - 03 February 2012
|
|
Scoping workshop
|
22 February 2012 (afternoon meeting) in London.
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Breast cancer (HER2 negative, oestrogen receptor positive) - everolimus [ID538]
|
|
Suggested remit
|
To appraise clinical and cost effectiveness of everolimus in combination with exemestane within its licensed indication for the treatment of human epidermal growth factor 2 (HER2) negative, oestrogen receptor positive locally advanced or metastatic breast cancer after prior endocrine therapy.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
03 January 2012 - 31 January 2012
|
|
Scoping workshop
|
14 February 2012 (morning meeting) in Manchester.
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Overactive bladder - mirabegron [ID542]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of mirabegron within its licensed indication for the treatment of overactive bladder.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
05 January 2012- 02 February 2012
|
|
Scoping workshop
|
20 February 2012 (afternoon meeting) in London.
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Benign prostatic hyperplasia - tadalafil (1st line) [ID534]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of tadalafil within its licensed indication for the treatment of benign prostatic hyperplasia
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
03 November 2011 - 01 December 2011
|
|
Scoping workshop
|
20 January 2012 (morning meeting) in Manchester
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Hypercholesterolemia (homozygous or severe heterozygous familial) - mipomersen (3rd or 4th line adjunct) [ID524]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of mipomersen, within its licensed indication for the prevention of cardiovascular events in people with homozygous or severe heterozygous familial hypercholesterolemia
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
03 November 2011 - 01 December 2011
|
|
Scoping workshop
|
20 January 2012 (afternoon meeting) in Manchester
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Epilepsy (partial, newly diagnosed) - zonisamide (1st line) [ID530]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of zonisamide monotherapy within its licensed indication for the treatment of partial onset seizures in epilepsy
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
02 November 2011 - 30 November 2011
|
|
Scoping workshop
|
16 January 2012 (morning meeting) in London
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Acute coronary syndrome - rivaroxaban [ID532]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of rivaroxaban within its licensed indication for the treatment of acute coronary syndrome
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
02 November 2011 - 30 November 2011
|
|
Scoping workshop
|
16 January 2012 (afternoon meeting) in London
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Rheumatoid arthritis (mod to severe, 2nd line) - tofacitinib [ID526]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of tofacitinibwithin its licensed indication for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
28 October 2011- 25 November 2011
|
|
Scoping workshop
|
12 January 2012 (afternoon meeting) in London
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Systemic juvenile idiopathic arthritis - canakinumab [ID533]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of canakinumab within its licensed indication for the treatment of systemic juvenile idiopathic arthritis.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
27 October 2011 - 24 November 2011
|
|
Scoping workshop
|
6 January 2012 (morning meeting) in London.
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
|
Topic
|
Multiple Myeloma - bortezomib (with autologous stem cell transplantation) [ID529]
|
|
Suggested remit
|
To appraise the clinical and cost effectiveness of bortezomib within its licensed indications as 1) induction treatment for people with newly diagnosed multiple myeloma, and 2) as consolidation therapy after autologous stem cell transplantation for people with multiple myeloma.
|
|
Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
|
27 October 2011 - 24 November 2011
|
|
Scoping workshop
|
9 January 2012 (morning meeting) in Manchester
|
|
Enquiries to
|
michelle.adhemar@nice.org.uk
|
|
Consultation document(s)
|
Draft scope
Provisional matrix
|
Back to top
This page was last updated: 24 May 2012
